272 related articles for article (PubMed ID: 35078648)
41. Molecular Classification Outperforms Histologic Classification in Prognostication of High-grade Endometrial Carcinomas With Undifferentiated and Sarcomatous Components.
Hammer PM; Wang A; Vermij L; Zdravkovic S; Heilbroner L; Ryan E; Geisick RLP; Charu V; Longacre TA; Suarez CJ; Ho C; Jenkins TM; Mills AM; Bosse T; Howitt BE
Am J Surg Pathol; 2024 May; ():. PubMed ID: 38780000
[TBL] [Abstract][Full Text] [Related]
42. Molecular classification defines outcomes and opportunities in young women with endometrial carcinoma.
Britton H; Huang L; Lum A; Leung S; Shum K; Kale M; Burleigh A; Senz J; Yang W; McConechy M; Kommoss S; Brucker S; Talhouk A; Gilks CB; McAlpine JN
Gynecol Oncol; 2019 Jun; 153(3):487-495. PubMed ID: 30922603
[TBL] [Abstract][Full Text] [Related]
43. Clinical factors as prognostic variables among molecular subgroups of endometrial cancer.
Kolehmainen A; Pasanen A; Tuomi T; Koivisto-Korander R; Bützow R; Loukovaara M
PLoS One; 2020; 15(11):e0242733. PubMed ID: 33232359
[TBL] [Abstract][Full Text] [Related]
44. Comprehensive immunomolecular profiling of endometrial carcinoma: A tertiary retrospective study.
Victoor J; Borght SV; Spans L; Lehnert S; Brems H; Laenen A; Vergote I; Van Gorp T; Van Nieuwenhuysen E; Han S; Timmerman S; Van Rompuy AS; Vanden Bempt I
Gynecol Oncol; 2021 Sep; 162(3):694-701. PubMed ID: 34253388
[TBL] [Abstract][Full Text] [Related]
45. Clear cell endometrial carcinomas with mismatch repair deficiency have a favorable prognosis: A systematic review and meta-analysis.
Travaglino A; Raffone A; Santoro A; Raimondo D; Angelico G; Valente M; Arciuolo D; Scaglione G; D'alessandris N; Casadio P; Inzani F; Mollo A; Seracchioli R; Zannoni GF
Gynecol Oncol; 2021 Sep; 162(3):804-808. PubMed ID: 34266691
[TBL] [Abstract][Full Text] [Related]
46. p53abn Endometrial Cancer: understanding the most aggressive endometrial cancers in the era of molecular classification.
Jamieson A; Thompson EF; Huvila J; Gilks CB; McAlpine JN
Int J Gynecol Cancer; 2021 Jun; 31(6):907-913. PubMed ID: 33589443
[TBL] [Abstract][Full Text] [Related]
47. Impact of molecular profile on prognosis and relapse pattern in low and intermediate risk endometrial cancer.
Lindemann K; Kildal W; Kleppe A; Tobin KAR; Pradhan M; Isaksen MX; Vlatkovic L; Danielsen HE; Kristensen GB; Askautrud HA
Eur J Cancer; 2024 Mar; 200():113584. PubMed ID: 38330767
[TBL] [Abstract][Full Text] [Related]
48. TCGA Molecular Prognostic Groups of Endometrial Carcinoma: Current Knowledge and Future Perspectives.
Arciuolo D; Travaglino A; Raffone A; Raimondo D; Santoro A; Russo D; Varricchio S; Casadio P; Inzani F; Seracchioli R; Mollo A; Mascolo M; Zannoni GF
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36232987
[TBL] [Abstract][Full Text] [Related]
49. Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry.
Vermij L; Jobsen JJ; León-Castillo A; Brinkhuis M; Roothaan S; Powell ME; de Boer SM; Khaw P; Mileshkin LR; Fyles A; Leary A; Genestie C; Jürgenliemk-Schulz IM; Crosbie EJ; Mackay HJ; Nijman HW; Nout RA; Smit VTHBM; Creutzberg CL; Horeweg N; Bosse T;
Br J Cancer; 2023 Mar; 128(7):1360-1368. PubMed ID: 36690721
[TBL] [Abstract][Full Text] [Related]
50. Molecular profile-based recommendations for postoperative adjuvant therapy in early endometrial cancer with high-intermediate or intermediate risk: a Chinese randomized phase III trial (PROBEAT).
Li Y; Zhu C; Xie H; Chen Y; Lv W; Xie X; Wang X
J Gynecol Oncol; 2023 Mar; 34(2):e37. PubMed ID: 36659832
[TBL] [Abstract][Full Text] [Related]
51. Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer.
Talhouk A; McConechy MK; Leung S; Yang W; Lum A; Senz J; Boyd N; Pike J; Anglesio M; Kwon JS; Karnezis AN; Huntsman DG; Gilks CB; McAlpine JN
Cancer; 2017 Mar; 123(5):802-813. PubMed ID: 28061006
[TBL] [Abstract][Full Text] [Related]
52. Integrated clinicopathologic and molecular analysis of endometrial carcinoma: Prognostic impact of the new ESGO-ESTRO-ESP endometrial cancer risk classification and proposal of histopathologic algorithm for its implementation in clinical practice.
de Biase D; Maloberti T; Corradini AG; Rosini F; Grillini M; Ruscelli M; Coluccelli S; Altimari A; Gruppioni E; Sanza V; Turchetti D; Galuppi A; Ferioli M; Giunchi S; Dondi G; Tesei M; Ravegnini G; Abbati F; Rubino D; Zamagni C; De Iaco P; Santini D; Ceccarelli C; Perrone AM; Tallini G; De Leo A
Front Med (Lausanne); 2023; 10():1146499. PubMed ID: 37064027
[TBL] [Abstract][Full Text] [Related]
53. Relationship between molecular markers and lymphadenectomy and lymphovascular space invasion in endometrial cancer.
Bilir F; Arıoz DT; Arıkan SE; Yalcın GS; Ozdemir C; Demir H; Chkhikvadze M; Ozdemir CY; Cicekli N; Vatansever N; Yılmaz S
Arch Gynecol Obstet; 2023 Sep; 308(3):941-946. PubMed ID: 36959366
[TBL] [Abstract][Full Text] [Related]
54. Prognostic significance of L1CAM expression in addition to ProMisE in endometrial cancer.
Kim J; Kim SI; Kim NR; Kim H; Kim HS; Chung HH; Kim JW; Lee C; Lee M
Gynecol Oncol; 2023 Jul; 174():231-238. PubMed ID: 37236032
[TBL] [Abstract][Full Text] [Related]
55. Prognosis of Stage I Endometrial Cancer According to the FIGO 2023 Classification Taking into Account Molecular Changes.
Dobrzycka B; Terlikowska KM; Kowalczuk O; Niklinski J; Kinalski M; Terlikowski SJ
Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38254879
[TBL] [Abstract][Full Text] [Related]
56. POLE, MMR, and MSI Testing in Endometrial Cancer: Proceedings of the ISGyP Companion Society Session at the USCAP 2020 Annual Meeting.
Casey L; Singh N
Int J Gynecol Pathol; 2021 Jan; 40(1):5-16. PubMed ID: 33290350
[TBL] [Abstract][Full Text] [Related]
57. Grade and Estrogen Receptor Expression Identify a Subset of No Specific Molecular Profile Endometrial Carcinomas at a Very Low Risk of Disease-Specific Death.
Jamieson A; Huvila J; Chiu D; Thompson EF; Scott S; Salvador S; Vicus D; Helpman L; Gotlieb W; Kean S; Samouelian V; Köbel M; Kinloch M; Parra-Harran C; Offman S; Grondin K; Irving J; Lum A; Senz J; Leung S; McConechy MK; Plante M; Kommoss S; Huntsman DG; Talhouk A; Gilks CB; McAlpine JN
Mod Pathol; 2023 Apr; 36(4):100085. PubMed ID: 36788084
[TBL] [Abstract][Full Text] [Related]
58. Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer-Combined Analysis of the PORTEC Cohorts.
Stelloo E; Nout RA; Osse EM; Jürgenliemk-Schulz IJ; Jobsen JJ; Lutgens LC; van der Steen-Banasik EM; Nijman HW; Putter H; Bosse T; Creutzberg CL; Smit VT
Clin Cancer Res; 2016 Aug; 22(16):4215-24. PubMed ID: 27006490
[TBL] [Abstract][Full Text] [Related]
59. Implementation of the 2021 molecular ESGO/ESTRO/ESP risk groups in endometrial cancer.
Imboden S; Nastic D; Ghaderi M; Rydberg F; Siegenthaler F; Mueller MD; Rau TT; Epstein E; Carlson JW
Gynecol Oncol; 2021 Aug; 162(2):394-400. PubMed ID: 34127276
[TBL] [Abstract][Full Text] [Related]
60. Molecular-based classification of endometrial carcinoma in Northern Thailand: impact on prognosis and potential for implementation in resource-limited settings.
Dankai W; Pongsuvareeyakul T; Phinyo P; Tejamai C; Teerapakpinyo C; Cheewakriangkrai C; Lekawanvijit S; Siriaunkgul S; Khunamornpong S
BMC Womens Health; 2023 Nov; 23(1):605. PubMed ID: 37964201
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
